Morgan Stanley Analysts Give Fresenius Medical Care AG & Co. KGAA (FME) a €90.00 Price Target

Fresenius Medical Care AG & Co. KGAA (ETR:FME) has been given a €90.00 ($107.14) price objective by investment analysts at Morgan Stanley in a research report issued on Monday. The firm presently has a “neutral” rating on the stock. Morgan Stanley’s price target would indicate a potential upside of 3.06% from the company’s previous close.

Several other equities analysts have also weighed in on FME. Berenberg Bank set a €95.60 ($113.81) price objective on shares of Fresenius Medical Care AG & Co. KGAA and gave the company a “buy” rating in a report on Tuesday, September 5th. Goldman Sachs Group set a €97.00 ($115.48) target price on shares of Fresenius Medical Care AG & Co. KGAA and gave the company a “buy” rating in a research note on Tuesday, September 12th. J P Morgan Chase & Co set a €95.10 ($113.21) target price on shares of Fresenius Medical Care AG & Co. KGAA and gave the company a “buy” rating in a research note on Thursday, September 14th. Finally, Deutsche Bank set a €83.00 ($98.81) target price on shares of Fresenius Medical Care AG & Co. KGAA and gave the company a “neutral” rating in a research note on Friday, October 20th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and nine have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of €89.06 ($106.03).

Fresenius Medical Care AG & Co. KGAA (ETR FME) opened at €87.33 ($103.96) on Monday. Fresenius Medical Care AG & Co. KGAA has a twelve month low of €73.60 ($87.62) and a twelve month high of €89.22 ($106.21).

TRADEMARK VIOLATION NOTICE: “Morgan Stanley Analysts Give Fresenius Medical Care AG & Co. KGAA (FME) a €90.00 Price Target” was posted by Transcript Daily and is the property of of Transcript Daily. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://transcriptdaily.com/2017/12/11/morgan-stanley-analysts-give-fresenius-medical-care-ag-90-00-price-target.html.

Fresenius Medical Care AG & Co. KGAA Company Profile

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. It offers dialysis treatment, and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized ESRD patients and for patients suffering from acute kidney failure.

Analyst Recommendations for Fresenius Medical Care AG & Co. KGAA (ETR:FME)

Receive News & Ratings for Fresenius Medical Care AG & Co. KGAA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGAA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply